Article
Effect of disclosing a polygenic risk score for coronary heart disease on adverse cardiovascular events: 10-year follow-up of the MI-GENES randomized clinical trial
2024-07-19
Abstract excerpt
<h4>Background</h4> The MI-GENES clinical trial ( NCT01936675 ), in which participants at intermediate risk of coronary heart disease (CHD) were randomized to receive a Framingham risk score (FRS g , n=103), or an integrated risk score (IRS g , n=104) that additionally included a polygenic risk score (PRS), demonstrated that after 6 months, participants randomized to IRS g had higher statin initiation and low...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- c44b9543-de24-5418-9e4e-5ceee0d81fd2
- DOI
- 10.1101/2024.07.19.24310709
